XNK Therapeutics Win Orphan Drug Status for Multiple Myeloma Immunotherapy

Stockholm-based XNK Therapeutics has secured an Orphan Drug designation from the FDA for its investigational cell therapy for the treatment of multiple myeloma.

The designation was supported by results from an early-stage trial in Sweden in which the immunotherapy demonstrated positive safety and tolerability. The company now plans to launch a phase 2 trial in Europe.

The immunotherapy previously received Orphan Drug status from the European Medicines Agency. XNK believes the therapy could be effective in treating a wide range of cancers.